885 related articles for article (PubMed ID: 16438660)
1. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
[TBL] [Abstract][Full Text] [Related]
3. Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus.
Almaula N; Ebersole BJ; Ballesteros JA; Weinstein H; Sealfon SC
Mol Pharmacol; 1996 Jul; 50(1):34-42. PubMed ID: 8700116
[TBL] [Abstract][Full Text] [Related]
4. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.
Porter RH; Benwell KR; Lamb H; Malcolm CS; Allen NH; Revell DF; Adams DR; Sheardown MJ
Br J Pharmacol; 1999 Sep; 128(1):13-20. PubMed ID: 10498829
[TBL] [Abstract][Full Text] [Related]
6. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
Nelson DL; Lucaites VL; Wainscott DB; Glennon RA
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):1-6. PubMed ID: 9933142
[TBL] [Abstract][Full Text] [Related]
8. Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2007 Oct; 571(2-3):156-65. PubMed ID: 17617403
[TBL] [Abstract][Full Text] [Related]
9. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.
Rosenzweig-Lipson S; Zhang J; Mazandarani H; Harrison BL; Sabb A; Sabalski J; Stack G; Welmaker G; Barrett JE; Dunlop J
Brain Res; 2006 Feb; 1073-1074():240-51. PubMed ID: 16430874
[TBL] [Abstract][Full Text] [Related]
10. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR
J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294
[TBL] [Abstract][Full Text] [Related]
11. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands.
Canal CE; Cordova-Sintjago T; Liu Y; Kim MS; Morgan D; Booth RG
J Pharmacol Exp Ther; 2013 Dec; 347(3):705-16. PubMed ID: 24080681
[TBL] [Abstract][Full Text] [Related]
12. Autoradiographic characterization of (+-)-1-(2,5-dimethoxy-4-[125I] iodophenyl)-2-aminopropane ([125I]DOI) binding to 5-HT2 and 5-HT1c receptors in rat brain.
Appel NM; Mitchell WM; Garlick RK; Glennon RA; Teitler M; De Souza EB
J Pharmacol Exp Ther; 1990 Nov; 255(2):843-57. PubMed ID: 2243353
[TBL] [Abstract][Full Text] [Related]
13. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
[TBL] [Abstract][Full Text] [Related]
14. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
15. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism.
Bishop C; Tessmer JL; Ullrich T; Rice KC; Walker PD
J Pharmacol Exp Ther; 2004 Aug; 310(2):687-94. PubMed ID: 15044557
[TBL] [Abstract][Full Text] [Related]
16. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
Schaerlinger B; Hickel P; Etienne N; Guesnier L; Maroteaux L
Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106
[TBL] [Abstract][Full Text] [Related]
17. Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation.
Wang CD; Gallaher TK; Shih JC
Mol Pharmacol; 1993 Jun; 43(6):931-40. PubMed ID: 8316224
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs.
Newton RA; Phipps SL; Flanigan TP; Newberry NR; Carey JE; Kumar C; McDonald B; Chen C; Elliott JM
J Neurochem; 1996 Dec; 67(6):2521-31. PubMed ID: 8931486
[TBL] [Abstract][Full Text] [Related]
19. Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury.
Obata H; Saito S; Sakurazawa S; Sasaki M; Usui T; Goto F
Pain; 2004 Mar; 108(1-2):163-9. PubMed ID: 15109520
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterisation of human 5-HT2 receptor subtypes.
Jerman JC; Brough SJ; Gager T; Wood M; Coldwell MC; Smart D; Middlemiss DN
Eur J Pharmacol; 2001 Feb; 414(1):23-30. PubMed ID: 11230991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
